Back to Startup Insights
DeepSeq.AI
DeepSeq.AI leverages a generative AI platform and high-throughput wet-lab assays to design optimized protein-based drugs. Its 'explainable AI' approach enables deep insight into protein function.
Headquarters
San Francisco, USA
Year Founded
2019
Founders
Dr. Mark Lee
Country
USA
Financial Information
Funding Stage
Pre-seed
Recent Funding
$500K
Funding By
Y Combinator
Core Technology
Explainable AI for proteins
Product Type
Drug
Pipeline Stage (Very Important)
Discovery
Regulatory Status
- IND Filed: No
- FDA/EMA Status: N/A
- Clinical Trial Registration: N/A
- Patents / IP Status: Filed
Partnerships
Pharma Collaborations
None
Academic / Hospital Tie-ups
Stanford University
CRO/CDMO Partnerships
None
Market & Differentiation
Explainable AI